XTL Biopharmaceuticals
XTLB
6 hedge funds and large institutions have $191K invested in XTL Biopharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
1.2% less ownership
Funds ownership: 2.07% → 0.87% (-1.2%)
28% less capital invested
Capital invested by funds: $266K → $191K (-$74.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$76.8K |
| 2 |
GI
GAMMA Investing
Foster City,
California
|
+$13K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$13K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$8.37K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$893 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $115K | – | – | – |
|
|
2
Citadel Advisors
Miami,
Florida
| $44K | +$76.8K | +18,967 | New |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $17.5K | +$13K | +3,212 | +74% |
|
|
GI
4
GAMMA Investing
Foster City,
California
| $7.47K | +$13K | +3,222 | New |
|
|
XT
5
XTX Topco
George Town,
Cayman Islands
| $5.94K | +$10.4K | +2,560 | New |
|
|
6
Morgan Stanley
New York
| $1.01K | -$8.37K | -2,068 | -83% |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$893 | -191 | Closed |
|
XTLB Hedge Fund Activity: Q4 2025 in Review
6 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2025, worth a combined $191K — down 28% from $266K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new XTLB positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $76.8K. The largest seller was Morgan Stanley, cutting an estimated $8.37K.
- 6 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2025, up from 4 in Q3 2025.
- Funds reported $191K of XTL Biopharmaceuticals stock for Q4 2025, down 28% quarter-over-quarter.
- 3 funds opened new XTL Biopharmaceuticals positions in Q4 2025 and 1 closed out, a net change of +2 holders.
- The largest XTL Biopharmaceuticals buyer in Q4 2025 was Citadel Advisors, an estimated $76.8K added.
- The largest XTL Biopharmaceuticals seller in Q4 2025 was Morgan Stanley, an estimated $8.37K sold.
Based on aggregated 13F filings for Q4 2025.